|  Company Statement

Tessera Therapeutics Awarded the Prix Galien USA 2023 for Best Startup

By Tessera Therapeutics

Tessera Therapeutics Awarded the Prix Galien USA 2023 for Best Startup

SOMERVILLE, Mass., October 27, 2023 -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced it was awarded the Prix Galien USA 2023 in the Best Startup category. The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health.

“The Prix Galien is one of the most prestigious awards across the biotech and biopharma industries, recognizing leading global scientific innovations poised to make the greatest health impact on humanity,” said Michael Severino, M.D., CEO of Tessera Therapeutics. “The judging panel, comprised of luminaries in pharma, biotech, and healthcare who have dedicated their lives to advancing promising solutions for patients, selected Tessera among a highly competitive field of nominees. This is an external recognition of what is in our DNA: we are cutting-edge science innovators and a creative, collaborative, and driven team. We are honored to be awarded this prize and remain steadfast in our pursuit of innovation to develop genetic medicines to transform human health.”

The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement. The Galien Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 15 countries.